Interrogating the RAS Interactome for New Therapeutic Opportunities

Time: 3:30 pm
day: Day Two Track D


  • Combining proximity labelling with CRISPR/Cas9 loss-of-function screening identified the interactomes of each RAS isoform
  • Mining these datasets for isoform-specific interactions identified PIP5K1A as specifically binding to and promoting oncogenic KRAS, but not NRAS or HRAS signalling and transformation, providing a new therapeutic opportunity
  • Mining these datasets for the top dependency identified EFR3A as a new RAS effector that recruits PI4KA to RAS in a positive feed-back loop that can be targeted to augment the anti-neoplastic activity of a G12C RAS inhibitor